Company Overview
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.
Why Investors Should Care
Generates a return on equity of 15.2%, reflecting efficient use of shareholder capital.
Revenue has grown at a 86.7% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $51.17M (+86.7% YoY); net profit $-21.81M.
- Trailing 12 Months Year-on-year growth — revenue -60.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 86.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 86.68% |
| 1 Year: | -60.80% |
Stock Price Performance
| 1 Year: | +65.21% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | +20.54% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- RSI (14)55.31 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 86.7% over 5 years.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SCTX Scribe Therapeutics Inc. PHARMA | 31.34 | -17.03 | $593.32M | 0.00% | - | 15.21% | 86.68% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 17.12M | 2.23M |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 22.68M | 14.66M |
| Operating Income | -5.56M | -12.43M |
| EBITDA | -2.28M | -15.75M |
| Interest Expense | 598.00K | 598.00K |
| Pretax Income | -3.74M | -17.12M |
| Tax Provision | -315.00K | 228.00K |
| Net Income | -3.42M | -17.35M |
| Diluted EPS | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Revenue | 27.41M | 51.17M |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 70.24M | 77.24M |
| Operating Income | -42.83M | -26.07M |
| EBITDA | -32.29M | -18.14M |
| Interest Expense | 2.38M | 2.39M |
| Pretax Income | -37.56M | -23.61M |
| Tax Provision | 10.22M | -1.80M |
| Net Income | -47.79M | -21.81M |
| Diluted EPS | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 127.97M | 78.22M |
| Current Assets | 110.37M | 66.93M |
| Cash & Equivalents | 12.60M | 12.80M |
| Inventory | - | - |
| Receivables | 3.52M | 7.35M |
| Total Liabilities | 253.83M | 221.64M |
| Current Liabilities | 35.02M | 69.06M |
| Long Term Debt | 34.47M | - |
| Total Debt | 41.68M | 41.43M |
| Total Equity | -125.86M | -143.42M |
| Shares Outstanding | - | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -45.23M | -45.21M |
| Investing Cash Flow | 13.01M | 45.27M |
| Financing Cash Flow | -222.00K | 142.00K |
| Capital Expenditure | -1.35M | -1.27M |
| Free Cash Flow | -46.58M | -46.48M |
| Net Change in Cash | -32.44M | 194.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | -156.2% | -50.9% |
| Net Margin % | -174.3% | -42.6% |
| ROE % | 38.0% | 15.2% |
| ROCE % | -46.1% | -284.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SCTX
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering without permanent genetic…
Scribe Therapeutics to Participate in Upcoming Investor Conferences
ALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lif…
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls
Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls
Scribe’s Genetic Editing Aims to Prevent Heart Attacks
Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can halve the risk of heart attacks and stroke…
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy life…
SCTX — Frequently Asked Questions
What is the current share price of Scribe Therapeutics Inc. (SCTX)?
As of 2026-09-19 21:16 PDT, Scribe Therapeutics Inc. (SCTX) trades at $31.34 on NasdaqGM. Its 52-week range is $18.06 to $37.25.
What is the market capitalisation of SCTX?
Scribe Therapeutics Inc. (SCTX) has a market capitalisation of $593.32M on NasdaqGM.
What is the P/E ratio of SCTX?
SCTX trades at a trailing price-to-earnings (P/E) ratio of -17.03. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.51.
What is the return on equity (ROE) of SCTX?
SCTX has a return on equity (ROE) of 15.21%.
Is SCTX a good stock to buy?
This page provides a data-driven analysis of Scribe Therapeutics Inc. (SCTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.